Related Experiment Video
Updated: Jun 11, 2026

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
Pre-Exercise Galactose or Lactose Reduces Glycaemic Excursions During Exercise in Adults With Type 1 Diabetes: A
Karoline R Schmidt1, Rakel F Johansen1, Simon B Riis2
1Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.
Aims:
To test whether pre-exercise galactose and lactose reduce glycaemic excursions during exercise compared with dextrose while maintaining protection against hypoglycaemia compared with placebo in adults with Type 1 diabetes METHODS: In a randomised, double-blind, 4-condition crossover trial, 14 adults with Type 1 diabetes completed four 60-min cycling sessions. Thirty minutes before exercise, participants consumed 20 g of dextrose, lactose, galactose, or placebo. The primary outcome was time to hypoglycaemia. Secondary outcomes included time in, below, and above range and glucose excursions.
Results:
Seven hypoglycaemic events occurred (none after dextrose, two after lactose, one after galactose, and four after placebo; p = 0.42), with no difference in time to hypoglycaemia. Time in range was lower for dextrose (48% [95% CI 40-57]) compared with lactose (70% [95% CI 62-78]), galactose (71% [95% CI 63-79]), and placebo (86% [95% CI 80-91]) (all p ≤ 0.01). Time below range was lower for dextrose (0% [95% CI 0-3]), lactose (1% [95% CI 0-5]), and galactose (1% [95% CI 0-5]) compared with placebo (8% [95% CI 4-14]) (all p < 0.05). Time above range was higher for DEX (52% [95% CI 44-60]), LAC (29% [95% CI 21-37]), and GAL (28% [95% CI 21-36]) compared with PLA (7% [95% CI 3-12], all p < 0.01).
Conclusions:
Pre-exercise galactose and lactose provide more stable glycaemic responses than dextrose and reduce time below range compared with placebo. These findings support their use as effective pre-exercise nutritional strategies in individuals with Type 1 diabetes.
Trial Registration:
ClinicalTrials.gov identifier: NCT05557227.
More Related Videos
12:59Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Hypoglycemia and Glucagon
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: